bpx-601
·Code: BPX-601
bpx-601: developed by 1 company · 1 clinical trial tracked.
bpx-601 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect bpx-601 to BLCM; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could bpx-601 → BLCM affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
metastatic castration-resistant prostate cancer and metastatic pancreatic cancer expressing PSCAProstate Cancer
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| BELLICUM PHARMACEUTICALS, INC (BLCM) metastatic castration-resistant prostate cancer and metastat… | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1, Open-Label, Dose-Escalation Study of BPX-601, an Anti-PSCA CAR T Cell Drug Product, in Relapsed/Refractory Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Occurrence of Treatment Emergent Adverse Events (TEAEs)
Interventionalopen36 targetStarted 2026-09Completion 2031-062 sites · United StatesRegeneron Pharmaceuticals
Frequently asked questions
Who is developing bpx-601?
bpx-601 is being developed by BELLICUM PHARMACEUTICALS, INC.
How many clinical trials involve bpx-601?
BioSniper tracks 1 clinical trial involving bpx-601.